Impact of Genotype-Guided Dosing on Anticoagulation Visits for Adults Starting Warfarin: A Randomized Controlled Trial

• Hafner JW , BelknapSM, SquillanteMD, BucheitKA. Adverse drug events in emergency department patients. Ann. Emerg. Med.39(3) , 258–267 (2002).
   PubMed Web of Science ®Google Scholar
• Levine MN , RaskobG, LandefeldS, KearonC. Hemorrhagic complications of anticoagulant treatment. Chest119(Suppl. 1) , S108–S121 (2001).
   PubMed Web of Science ®Google Scholar
• Fihn SD , McDonellM, MartinD et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann. Intern. Med. 118(7) , 511–520 (1993).
   PubMed Web of Science ®Google Scholar
• Landefeld CS , BeythRJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am. J. Med.95(3) , 315–328 (1993).
   PubMed Web of Science ®Google Scholar
• Gage BF , EbyC, MilliganPE, BanetGA, DuncanJR, McLeodHL. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb. Haemost.91(1) , 87–94 (2004).
   PubMed Web of Science ®Google Scholar
• Jonas DE , McLeodHL. Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol. Sci.30(7) , 375–386 (2009).
   PubMed Web of Science ®Google Scholar
• Wadelius M , ChenLY, LindhJD et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113(4) , 784–792 (2009).
   PubMed Web of Science ®Google Scholar
• Klein TE , AltmanRB, ErikssonN et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8) , 753–764 (2009).
   PubMed Web of Science ®Google Scholar
• Sconce EA , KhanTI, WynneHA et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106(7) , 2329–2333 (2005).
   PubMed Web of Science ®Google Scholar
• Aquilante CL , LangaeeTY, LopezLM et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharmacol. Ther. 79(4) , 291–302 (2006).
   PubMed Web of Science ®Google Scholar
• Tham LS , GohBC, NafzigerA et al. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin. Pharmacol. Ther. 80(4) , 346–355 (2006).
   PubMed Web of Science ®Google Scholar
• Herman D , PeternelP, StegnarM, BreskvarK, DolzanV. The influence of sequence variations in factor VII, γ-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb. Haemost.95(5) , 782–787 (2006).
   PubMed Web of Science ®Google Scholar
• Miao L , YangJ, HuangC, ShenZ. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur. J. Clin. Pharmacol.63(12) , 1135–1141 (2007).
   PubMed Web of Science ®Google Scholar
• Wu AH , WangP, SmithA et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 9(2) , 169–178 (2008).
   PubMed Web of Science ®Google Scholar
• Burmester JK , BergRL, YaleSH et al. A randomized controlled trial of genotype-based Coumadin initiation. Genet. Med. 13(6) , 509–518 (2011).
   PubMed Web of Science ®Google Scholar
• Anderson JL , HorneBD, StevensSM et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116(22) , 2563–2570 (2007).
   PubMed Web of Science ®Google Scholar
• Anderson JL , HorneBD, StevensSM et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 125(16) , 1997–2005 (2012).
   PubMed Web of Science ®Google Scholar
• Caraco Y , BlotnickS, MuszkatM. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin. Pharmacol. Ther.83(3) , 460–470 (2008).
   PubMed Web of Science ®Google Scholar
• Ansell J , HirshJ, HylekE, JacobsonA, CrowtherM, PalaretiG. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest133(Suppl. 6) , S160–S198 (2008).
   PubMed Web of Science ®Google Scholar
• Gage BF , EbyC, JohnsonJA et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84(3) , 326–331 (2008).
   PubMed Web of Science ®Google Scholar
• Rosendaal FR , CannegieterSC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb. Haemost.69(3) , 236–239 (1993).
   PubMed Web of Science ®Google Scholar
• Jonas DE , Bryant Shilliday B, Laundon WR, Pignone M. Patient time requirements for anticoagulation therapy with warfarin. Med. Decis. Making30(2) , 206–216 (2010).
   PubMed Web of Science ®Google Scholar
• Borgiani P , CiccacciC, ForteV et al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics10(2) , 261–266 (2009).
   PubMed Web of Science ®Google Scholar
• Caldwell MD , AwadT, JohnsonJA et al. CYP4F2 genetic variant alters required warfarin dose. Blood111(8) , 4106–4112 (2008).
   PubMed Web of Science ®Google Scholar
• Ferder NS , EbyCS, DeychE et al. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J. Thromb. Haemost. 8(1) , 95–100 (2010).
   PubMed Web of Science ®Google Scholar

▪ Websites

• RxList. The internet drug index. www.rxlist.com/script/main/art.asp?articlekey=79510
   Google Scholar
• Random.org homepage. www.random.org
   Google Scholar
• WarfarinDosing.org homepage. www.warfarindosing.org
   Google Scholar
• University of Pennsylvania. Clarification of optimal anticoagulation through genetics (COAG): a randomized, multicenter, double-blind clinical trial to evaluate efficacy in the use of clinical plus genetic information to guide warfarin therapy initiation and improve anticoagulation control for patients. http://coagstudy.org
   Google Scholar